Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with  Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with  Acquired Hypothalamic Obesity#Rhythm #Pharmaceuticals #Announce #Topline #Results #Pivotal #Phase #TRANSCEND #Trial #Evaluating #Setmelanotide #Patients #Acquired #Hypothalamic #Obesity